AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7011349 — intervention group
Group type: EXPERIMENTAL
Intervention: aminophylline, salbutamol (AS)
Number of subjects: 4
Study 31997718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh Water Bath (FWB)
Number of subjects: 11
Study 31997718 — intervention group
Group type: COMPARATOR
Intervention: Salt Water Bath (SWB)
Number of subjects: 11
Study 30144242 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment (antimycotic or steroid) and probiotic
Number of subjects: 22
Study 30144242 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study 28898920 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy
Number of subjects: 337
Study 28898920 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 337
Study 25679130 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oral morphine (SROM)
Number of subjects: 157
Study 25679130 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 157
Study 25438680 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.5 mg/kg)
Number of subjects: 40
Study 25438680 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamylal (1.5 mg/kg)
Number of subjects: 40
Study 22909145 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 0.03 mg/drospirenone 3 mg/levomefolate calcium 0.451 mg (SAFYRAL®)
Number of subjects: 45
Study 22909145 — intervention group
Group type: COMPARATOR
Intervention: EE 0.03 mg/drospirenone 3 mg (Yasmin®)
Number of subjects: 45
Study 22909145 — intervention group
Group type: COMPARATOR
Intervention: levomefolate calcium 0.451 mg
Number of subjects: 45
Study 20099307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia nervosa (BN) group
Number of subjects: 25
Study 20099307 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (NC) group
Number of subjects: 25
Study 18056882 — intervention group
Group type: EXPERIMENTAL
Intervention: Push-button response method
Number of subjects: 30
Study 18056882 — intervention group
Group type: COMPARATOR
Intervention: Hand-raise response method
Number of subjects: 30
Study 18056882 — intervention group
Group type: COMPARATOR
Intervention: Verbal response method
Number of subjects: 30
Study 18056882 — intervention group
Group type: EXPERIMENTAL
Intervention: All response methods
Number of subjects: 30
Study 16230721 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin plus oral agents (n = 103)
Number of subjects: 309
Study 16230721 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin alone (n = 104)
Number of subjects: 309
Study 16230721 — intervention group
Group type: COMPARATOR
Intervention: Oral agent therapy alone (n = 99)
Number of subjects: 309
Study 12173326 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate (EMP) as first-line therapy
Number of subjects: 386
Study 12173326 — intervention group
Group type: COMPARATOR
Intervention: No further therapeutic intervention (Control group)
Number of subjects: 386
Study 10203381 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV plus ddl
Number of subjects: 1280
Study 10203381 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV plus ddC
Number of subjects: 1280
Study 10203381 — intervention group
Group type: COMPARATOR
Intervention: ZDV alone
Number of subjects: 1280
Study 7781349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (2 g IV)
Number of subjects: 135
Study 7781349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IV)
Number of subjects: 135
Study 7781349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (2 g IV) in severe group
Number of subjects: 135
Study 7781349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IV) in severe group
Number of subjects: 135
Study 7781349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (2 g IV) in moderate group
Number of subjects: 135
Study 7781349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IV) in moderate group
Number of subjects: 135
Study 2278325 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interpleural analgesia with 20 ml bupivacaine 0.5% with adrenaline 5 micrograms/ml
Number of subjects: 0
Study 2278325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2278325 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interpleural analgesia with bupivacaine
Number of subjects: 0
Study 2278325 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of interpleural bupivacaine and systemic morphine
Number of subjects: 0
Study 2278325 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine regimen
Number of subjects: 0
Study 758795 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in coping and social skills (behavioral training)
Number of subjects: 121
Study 758795 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 121
Study 31794324 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine + ATRA
Number of subjects: 200
Study 31794324 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine + Valproate
Number of subjects: 200
Study 31794324 — intervention group
Group type: COMPARATOR
Intervention: Decitabine alone
Number of subjects: 200
Study 31702761 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry +health™ cranberry supplement (cranberry chew)
Number of subjects: 20
Study 31702761 — intervention group
Group type: COMPARATOR
Intervention: Placebo chew
Number of subjects: 20
Study 29090491 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI Group (MG) - Accent MRI™ conditional pacing system, n = 140
Number of subjects: 283
Study 29090491 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - Standard device interrogation and clinical evaluation, n = 143
Number of subjects: 283
Study 24924522 — intervention group
Group type: EXPERIMENTAL
Intervention: Soyabean meal (SB)
Number of subjects: 18
Study 24924522 — intervention group
Group type: COMPARATOR
Intervention: Whey proteins (WP)
Number of subjects: 18
Study 23541423 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol 200 mg/day
Number of subjects: 510
Study 23541423 — intervention group
Group type: COMPARATOR
Intervention: no medication (control group)
Number of subjects: 510
Study 21692286 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridian‐collateral electric information therapy combined with pricking and cupping
Number of subjects: 200
Study 21692286 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir administered orally
Number of subjects: 200
Study 19747869 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised home-based exercise (3 sessions a week of stationary cycling) for 10 weeks
Number of subjects: 12
Study 19747869 — intervention group
Group type: COMPARATOR
Intervention: Control group maintained usual daily activity
Number of subjects: 12
Study 19747869 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised home-based exercise
Number of subjects: 12
Study 16697308 — intervention group
Group type: EXPERIMENTAL
Intervention: Para-Hisian pacing
Number of subjects: 16
Study 16697308 — intervention group
Group type: COMPARATOR
Intervention: Right apical pacing
Number of subjects: 16
Study 15110211 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-infarction left atrial remodeling
Number of subjects: 514
Study 15110211 — intervention group
Group type: EXPERIMENTAL
Intervention: Relation of left atrial remodeling to left ventricular remodeling
Number of subjects: 514
Study 14750569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral or intravitreal injection of 0.1 mL antibiotic (40 microg gentamicin and 45 microg clindamycin)
Number of subjects: 60
Study 14750569 — intervention group
Group type: COMPARATOR
Intervention: Balanced saline solution (BSS) injection
Number of subjects: 60
Study 9662313 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily placement of prostaglandin gel
Number of subjects: 105
Study 9662313 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily membrane stripping
Number of subjects: 105
Study 9662313 — intervention group
Group type: COMPARATOR
Intervention: Daily cervical examinations
Number of subjects: 105
Study 10208998 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg/d) and colestipol (30 g/d)
Number of subjects: 88
Study 10208998 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin (4 g/d) and colestipol
Number of subjects: 88
Study 10208998 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with placebo alone or with colestipol
Number of subjects: 88
Study 10208998 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 88
Study 2142911 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide (600 mg daily for six months)
Number of subjects: 51
Study 2142911 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to picotamide)
Number of subjects: 51
Study 333540 — intervention group
Group type: EXPERIMENTAL
Intervention: Feprazone
Number of subjects: 24
Study 333540 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 24
Study 31554917 — intervention group
Group type: EXPERIMENTAL
Intervention: MO-lower-IR
Number of subjects: 68
Study 31554917 — intervention group
Group type: COMPARATOR
Intervention: MO-higher-IR
Number of subjects: 68
Study 31554917 — intervention group
Group type: EXPERIMENTAL
Intervention: MO-metf-T2DM
Number of subjects: 68
Study 31781825 — intervention group
Group type: EXPERIMENTAL
Intervention: Credé maneuver
Number of subjects: 148
Study 31781825 — intervention group
Group type: COMPARATOR
Intervention: Non-Credé maneuver
Number of subjects: 148
Study 31781825 — intervention group
Group type: EXPERIMENTAL
Intervention: Credé maneuver (mixed urinary incontinence)
Number of subjects: 148
Study 31781825 — intervention group
Group type: COMPARATOR
Intervention: Non-Credé maneuver (mixed urinary incontinence)
Number of subjects: 148
Study 27197120 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 11
Study 27197120 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin H)
Number of subjects: 11
Study 24374394 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic solution (LAS) applied to the columella (2 mL of 2% prilocaine with 1:80,000 adrenaline)
Number of subjects: 47
Study 24374394 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic solution (LAS) applied to the nasal dorsum (2 mL of 2% prilocaine with 1:80,000 adrenaline)
Number of subjects: 47
Study 24374394 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic solution (LAS) applied to the nasal dorsum followed by LAS to the columella after 10 minutes (2 mL of 2% prilocaine with 1:80,000 adrenaline)
Number of subjects: 47
Study 23400883 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocacy intervention
Number of subjects: 200
Study 23400883 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 21537645 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive acupuncture (PA) group, n = 12
Number of subjects: 24
Study 21537645 — intervention group
Group type: COMPARATOR
Intervention: Control group (CT), n = 12
Number of subjects: 24
Study 19663305 — intervention group
Group type: EXPERIMENTAL
Intervention: inulin fortified spoon yoghurt
Number of subjects: 76
Study 19663305 — intervention group
Group type: EXPERIMENTAL
Intervention: kefir drink
Number of subjects: 76
Study 19663305 — intervention group
Group type: EXPERIMENTAL
Intervention: drinking yoghurt
Number of subjects: 76
Study 17086465 — intervention group
Group type: EXPERIMENTAL
Intervention: 4:00 PM inhalation of 4.5% saline
Number of subjects: 18
Study 17086465 — intervention group
Group type: EXPERIMENTAL
Intervention: 4:00 AM inhalation of 4.5% saline
Number of subjects: 18
Study 15583260 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe storage of medicines
Number of subjects: 3906
Study 15583260 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of smoke alarms
Number of subjects: 3906
Study 15583260 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage of sharp objects
Number of subjects: 3906
Study 15583260 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of availability of fireguards
Number of subjects: 3906
Study 15583260 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of availability of stair gates
Number of subjects: 3906
Study 15583260 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of availability of cupboard locks
Number of subjects: 3906
Study 15583260 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for help fitting fireguards
Number of subjects: 3906
Study 15583260 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for help fitting stair gates
Number of subjects: 3906
Study 15583260 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for help fitting cupboard locks
Number of subjects: 3906
Study 11704585 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler (0.25 mg terbutaline)
Number of subjects: 13
Study 11704585 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler (0.5 mg terbutaline)
Number of subjects: 13
Study 11704585 — intervention group
Group type: EXPERIMENTAL
Intervention: pMDI (0.25 mg terbutaline)
Number of subjects: 13
Study 11704585 — intervention group
Group type: EXPERIMENTAL
Intervention: pMDI (0.5 mg terbutaline)
Number of subjects: 13
Study 9470838 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ‐C30 (version 1) questionnaire assessing physical functioning, role functioning, global health/QoL scales, and a single pain item.
Number of subjects: 638
Study 8188891 — intervention group
Group type: EXPERIMENTAL
Intervention: Fumaric acid derivatives
Number of subjects: 100
Study 8188891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2917596 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Methoxypsoralen (5-MOP) 40 mg/day
Number of subjects: 12
Study 2917596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31696603 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-dose (PHEN/TPM 7.5 mg/46 mg)
Number of subjects: 42
Study 31696603 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-dose (PHEN/TPM 15 mg/92 mg)
Number of subjects: 42
Study 31696603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31696603 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-dose
Number of subjects: 42
Study 31696603 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-dose
Number of subjects: 42
Study 30649270 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP)
Number of subjects: 1166
Study 30649270 — intervention group
Group type: COMPARATOR
Intervention: Dual-Chamber Pacing (DDDR)
Number of subjects: 1166
Study 28520768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone reminders and peer counseling
Number of subjects: 242
Study 25786566 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Number of subjects: 54
Study 25786566 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 54
Study 23450015 — intervention group
Group type: EXPERIMENTAL
Intervention: Durasul highly cross‐linked polyethylene
Number of subjects: 90
Study 23450015 — intervention group
Group type: COMPARATOR
Intervention: Sulene polyethylene
Number of subjects: 90
Study 21254055 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 30
Study 21254055 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 30
Study 18379058 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% w/v d-limonene
Number of subjects: 0
Study 18379058 — intervention group
Group type: EXPERIMENTAL
Intervention: d-limonene (100 mumol/kg/body wt for 5 days)
Number of subjects: 0
Study 18379058 — intervention group
Group type: COMPARATOR
Intervention: Cumulative skin irritation and sensitization
Number of subjects: 0
Study 18379058 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch adhesion
Number of subjects: 0
Study 16441467 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week triple therapy for eradication of H. pylori
Number of subjects: 51
Study 16441467 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole plus placebo
Number of subjects: 51
Study 16441467 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover open-label triple therapy
Number of subjects: 51
Study 12969090 — intervention group
Group type: EXPERIMENTAL
Intervention: HM-CAP (immunoglobulin-G)
Number of subjects: 93
Study 12969090 — intervention group
Group type: EXPERIMENTAL
Intervention: PP-CAP (immunoglobulin-A)
Number of subjects: 93
Study 12969090 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyloriset EIA-G
Number of subjects: 93
Study 10710743 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist leuprolide acetate, 3.75 mg intramuscularly every 28 days
Number of subjects: 21
Study 10710743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9018513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (120 mg)
Number of subjects: 10
Study 9018513 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10
Study 9018513 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 10
Study 9018513 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with Pseudoephedrine
Number of subjects: 10
Study 1588267 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour intensive training course on interpretation of electrocardiography in myocardial infarction
Number of subjects: 16
Study 1588267 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 16
Study 3903644 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (1 mg/kg, intravenous)
Number of subjects: 10
Study 3903644 — intervention group
Group type: COMPARATOR
Intervention: Bethanechol (0.075 mg/kg, subcutaneous)
Number of subjects: 10
Study 31348415 — intervention group
Group type: EXPERIMENTAL
Intervention: The First Twenty® (TF20) program, a web-based health and wellness program with nutrition, physical activity, and behavioral health components.
Number of subjects: 10
Study 31348415 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified in detail).
Number of subjects: 10
Study 29066028 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B2: 80 kVp, 30 ml of iohexol at 4.5 ml/s; hybrid iterative reconstruction (HIR) and IMR.
Number of subjects: 60
Study 29066028 — intervention group
Group type: COMPARATOR
Intervention: Group A: 120 kVp, 50 ml of iopromide at a flow rate of 5 ml/s; filtered back projection (FBP) reconstruction.
Number of subjects: 60
Study 28683245 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 48
Study 28683245 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 48
Study 28683245 — intervention group
Group type: COMPARATOR
Intervention: Nasal congestion index (NCI)
Number of subjects: 48
Study 24041792 — intervention group
Group type: EXPERIMENTAL
Intervention: ITX5061 150 mg/day for 28 days (C150)
Number of subjects: 30
Study 24041792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24041792 — intervention group
Group type: EXPERIMENTAL
Intervention: ITX5061 150 mg/day for 3 days (A150)
Number of subjects: 30
Study 24041792 — intervention group
Group type: EXPERIMENTAL
Intervention: ITX5061 150 mg/day for 14 days (B150)
Number of subjects: 30
Study 22705785 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus strain L-55-contained yogurt
Number of subjects: 0
Study 22705785 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 0
Study 19798072 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise
Number of subjects: 234
Study 19558057 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU of intravenous heparin during surgery
Number of subjects: 50
Study 19558057 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 50
Study 16023510 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal midazolam
Number of subjects: 177
Study 16023510 — intervention group
Group type: COMPARATOR
Intervention: Rectal diazepam
Number of subjects: 177
Study 16023510 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal midazolam and Rectal diazepam
Number of subjects: 177
Study 12399203 — intervention group
Group type: EXPERIMENTAL
Intervention: H-B-VAXII (0.5 ml, 5 micro g HBsAg) intramuscular injection at birth, 1, and 6 months (Schedule A)
Number of subjects: 97
Study 12399203 — intervention group
Group type: EXPERIMENTAL
Intervention: H-B-VAXII (0.5 ml, 5 micro g HBsAg) intramuscular injection at birth, 1, 2, and 12 months (Schedule B)
Number of subjects: 97
Study 10344062 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg
Number of subjects: 80
Study 10344062 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 2.5 mg
Number of subjects: 80
Study 10344062 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 2.5 mg
Number of subjects: 80
Study 10344062 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg
Number of subjects: 80
Study 10344062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 7855576 — intervention group
Group type: EXPERIMENTAL
Intervention: Central bearing point method
Number of subjects: 40
Study 7855576 — intervention group
Group type: EXPERIMENTAL
Intervention: Protrusive check-bite method
Number of subjects: 40
Study 7855576 — intervention group
Group type: EXPERIMENTAL
Intervention: Protrusive bite record integrated in the bite fork
Number of subjects: 40
Study 7855576 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods combined
Number of subjects: 40
Study 1775523 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazepam (30‐60 mg)
Number of subjects: 118
Study 1775523 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (75‐150 mg)
Number of subjects: 118
Study 6126413 — intervention group
Group type: EXPERIMENTAL
Intervention: Timiperone
Number of subjects: 205
Study 6126413 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 205
Study 31804659 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard multimodal treatment
Number of subjects: 0
Study 31804659 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0